Financial Data and Key Metrics Changes - Total revenue for Q4 2025 decreased by 14.8% to $7.7 million compared to $9.1 million in Q4 2024, primarily due to the expiration of Gamma Knife contracts and lower proton beam radiation therapy volumes [12] - For the full year 2025, total revenue was $28.1 million, slightly down from $28.3 million in 2024 [13] - Gross margin for Q4 2025 was approximately $906 thousand or 12%, down from 35% in Q4 2024, reflecting lower treatment volumes and a shift towards direct patient services [13] - Net loss attributable to the company improved to $631 thousand or $0.09 per diluted share, compared to a net loss of $1.6 million or $0.23 per diluted share in the prior year [13] - Adjusted EBITDA for the full year was $5.5 million, down from $8.9 million in 2024 [16] Business Line Data and Key Metrics Changes - Revenue from direct patient care services increased by 23.7% to $15.5 million, while leasing revenue declined to $12.6 million [14] - LINAC revenue increased by 35.4% to $11.5 million, while Gamma Knife revenue decreased by 5.5% to $9.2 million, and proton beam radiation therapy revenue declined by 26% to $7.4 million [14] - LINAC treatment sessions more than doubled to 28,147 in 2025, marking the first full year of operations for both Puebla and Rhode Island centers [14] Market Data and Key Metrics Changes - The international business remains a strong contributor, with successful operations in Puebla, Mexico, and leadership positions in Ecuador and Peru [10] - The company is developing a new center in Guadalajara, Mexico, expected to begin operations in 2026, which represents significant future opportunity [10] Company Strategy and Development Direction - The company is focused on strengthening health system partnerships, expanding clinical capabilities, and enhancing patient access to advanced cancer care [4] - A transition towards a direct patient care model is underway, which now represents the majority of revenue and provides a stable platform for long-term growth [4] - Future priorities include increasing treatment volumes, driving operational efficiencies, and expanding the footprint through disciplined development [11] Management's Comments on Operating Environment and Future Outlook - Management acknowledged challenges in 2025, including physician turnover and reimbursement dynamics, but emphasized decisive actions taken to address these issues [5] - The company is optimistic about 2026, citing a strong foundation for future growth supported by partnerships and expanded clinical capacity [11] - Ongoing discussions with lenders regarding capital structure enhancements are constructive, aiming to support long-term growth initiatives [6] Other Important Information - The company ended 2025 with approximately $3.7 million in cash, down from $11.3 million at the end of 2024, primarily due to capital expenditures related to expansion [16] - Total debt at year-end was approximately $17.3 million, with certain financial covenants not met due to lower profitability and higher operating costs [17] Q&A Session Summary Question: Will the company be able to offset revenue declines from expired contracts by referring patients between centers in Rhode Island? - Management confirmed that leveraging infrastructure across a larger footprint is part of the strategy in Rhode Island [21] Question: What is the timeline for constructing the new facility in Rhode Island and staffing it? - The Bristol facility is expected to come online in late 2027, followed by the proton facility in 2028, with staffing initiatives starting several months in advance [22] Question: Why were the expired contracts not disclosed earlier? - Management explained that the expiration of contracts was previously mentioned, and the health systems opted to update their equipment independently [28][31] Question: Will the company be profitable in 2026? - Management refrained from speculating on profitability for 2026, emphasizing that foundational issues have been addressed [35] Question: Is the company constrained from buying back stock due to credit agreements? - Management indicated that the company has not been interested in a stock buyback program and that current lender conditions make it unlikely to change this stance [44]

Investor Day 2026 CAUTIONARY STATEMENTS Forward-Looking Statements: This presentation includes "forward-looking statements" within the meaning of U.S. federal securities laws. Forward-looking statements are any statements other than statements of historical fact. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from these statements. Forward-looking statements are often identified by words like "will," "may," "could," "should," "would," "believe," ...

Summary of Precigen Conference Call Company Overview - **Company**: Precigen - **Key Product**: Papzimeos, an immunotherapy for recurrent respiratory papillomatosis (RRP) - **Leadership**: Helen Sabzevari (President and CEO), Phil Tennant (Chief Commercial Officer) Core Industry Insights - **FDA Approval**: Papzimeos received FDA approval, marking a significant milestone for Precigen as it transitions into a commercial stage entity [1] - **Market Need**: RRP has historically lacked effective treatments, with patients often undergoing multiple surgeries, leading to severe complications [10][11] - **Patient Demographics**: RRP can affect both children and adults, with severe cases requiring numerous surgeries annually [10][11] Product Details - **Mechanism of Action**: Papzimeos utilizes a unique gorilla adenovirus platform, allowing for a higher capacity of gene presentation (up to 12 KB) and the ability to administer multiple doses without immunogenicity issues [4][5] - **Clinical Efficacy**: In pivotal studies, Papzimeos demonstrated a 51% complete response rate and an 86% overall reduction in surgeries among patients [15][16] - **Safety Profile**: The treatment has shown a favorable safety profile, comparable to receiving a flu shot [61] Commercial Strategy - **Launch Metrics**: The company began dosing patients in November, with a straightforward regimen of four subcutaneous injections over 12 weeks [20][21] - **Market Focus**: Precigen identified approximately 500 hospital systems as key targets for initial commercialization, with a focus on large academic centers and community hospitals [25] - **Patient Engagement**: The company is actively working with patient advocacy groups to raise awareness and ensure patients are informed about treatment options [33][36] Future Plans - **Redosing Studies**: Ongoing studies aim to convert partial responders to complete responders through additional dosing [19][62] - **Pediatric Trials**: Plans to initiate pediatric trials by the end of 2026, expanding the treatment's applicability to younger patients [62] - **Platform Expansion**: Development of PRGN-2009, targeting HPV-related cancers, is underway, leveraging the same adenovirus platform as Papzimeos [64][65] Financial Outlook - **Revenue Projections**: The company anticipates significant revenue growth from Papzimeos, with expectations of reaching break-even by the end of 2026 [82] - **Funding Utilization**: With over $100 million in the bank, Precigen plans to allocate resources towards redosing studies, pediatric trials, and the expansion of PRGN-2009 [84] Key Challenges and Considerations - **Payer Access**: While the company has seen positive payer coverage, some restrictions exist based on prior surgical history [47][49] - **Market Education**: Continuous efforts are needed to educate healthcare providers and patients about RRP and the new treatment options available [36][37] Conclusion Precigen is positioned to make a significant impact in the treatment of RRP with Papzimeos, addressing a long-standing unmet medical need. The company's innovative approach, combined with strategic commercialization efforts and future expansion plans, suggests a promising outlook for both patient outcomes and financial performance.

Summary of Allied Gold Corporation's Extraordinary General Meeting Company Overview - **Company**: Allied Gold Corporation (NYSE: AAUC) - **Industry**: Gold Mining - **Meeting Date**: March 31, 2026 - **Key Transaction**: Arrangement with Zijin Gold International Company Limited Core Points and Arguments - **Meeting Structure**: The meeting was called to order by the Chairman and CEO, Peter Marrone, with voting procedures outlined for shareholders present [1][2][3] - **Quorum Confirmation**: A quorum was confirmed with sufficient proxies received, allowing the meeting to proceed [5] - **Arrangement Resolution**: Shareholders were asked to approve a special resolution for a plan of arrangement with Zijin Gold, requiring at least two-thirds approval from shareholders [5][6] - **Transaction Details**: The arrangement involves an all-cash offer of CAD 44 per share, totaling $5.5 billion, representing a 27% premium to the average share price prior to the announcement [21] - **Shareholder Support**: The transaction received overwhelming approval from shareholders, with more than 99% voting in favor [24] Company Performance and Strategy - **Production Growth**: The company expects a 55% increase in production levels in 2026 compared to 2023, driven by the Kurmuk mine coming into production and the completion of Sadiola's first phase expansion [14][15] - **Cash Flow Improvement**: Operating cash flow has seen exponential growth, with a strong focus on lowering costs and increasing margins [14][15] - **Asset Overview**: The company operates two Tier One generational mines, Sadiola and Kurmuk, with significant production capabilities and a large mineral inventory [10][12][13] - **Strategic Review**: A strategic review was conducted to enhance geographical diversification and maximize shareholder value, leading to the decision to engage with Zijin Gold [18][20] Financial Health - **Cash Position**: The company ended the previous year with $480 million in cash, indicating strong financial health and full funding for growth initiatives [16] - **Market Performance**: Allied Gold's share price increased 3.7 times, outperforming peers and indices like GDXJ, which saw increases of 200% and 230% respectively [17][18] Regulatory and Completion Process - **Transaction Timeline**: The agreement allows until the end of May for completion, with provisions for extensions if necessary [23] - **Regulatory Approvals**: Both companies are working cooperatively to secure necessary regulatory approvals, with a focus on a sensible approach to the geopolitical environment [24][25] Conclusion - **Future Outlook**: The transaction with Zijin is seen as a validation of the company's value and a means to mitigate market volatility, positioning Allied Gold as a differentiated asset class in the gold mining industry [25][26] - **Continued Operations**: The company plans to continue regular operations and will publish its fourth-quarter results, indicating that it remains on track with production and cost budgets [26][27]

Financial Data and Key Metrics Changes - As of December 31, 2025, cash and cash equivalents were $8.8 million, reflecting disciplined cash management and net proceeds from warrant exercises and targeted ATM usage during the year [18] - Research and development expenses for 2025 were $7.8 million, significantly lower than 2024, primarily due to the completion of the OVATION 2 study [18] - General and administrative expenses decreased by 8% year-over-year through streamlined operations [19] - Net loss for 2025 was $14.5 million or $6.83 per share, compared to $18.6 million or $16.94 per share in 2024, indicating meaningful improvement driven by cost discipline [19] Business Line Data and Key Metrics Changes - The proprietary IL-12 immunotherapy, IMNN-001, is advancing in the OVATION 3 pivotal Phase III study, with strong momentum following the transformational year in 2025 [4][5] - The OVATION 2 study demonstrated a median overall survival benefit of 14.7 months, with patients treated with PARP inhibitors showing a median increase in overall survival of more than two years [7][8] Market Data and Key Metrics Changes - Enrollment in the OVATION 3 trial is ahead of plan, with seven clinical sites actively enrolling patients and up to 43 additional centers under evaluation [10] - The trial design includes interim analyses for early efficacy stopping rules, providing 95% power on the primary endpoint of overall survival [11] Company Strategy and Development Direction - The company is focused on advancing the OVATION 3 study while navigating a challenging capital markets environment, emphasizing a multi-pronged financing strategy [15][16] - The strategic reorganization aims to reduce non-essential costs and sharpen operational focus exclusively on the OVATION 3 trial [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing momentum of the OVATION 3 trial and the potential for significant value creation for shareholders [15][75] - The company is encouraged by continued interest in potential non-dilutive partnerships for its TheraPlas technology platform and IMNN-001 [16] Other Important Information - The Phase II MRD study has successfully capped enrollment at 30 patients, aligning with the overall survival benefits shown in the OVATION 2 study [12] - The company is actively considering expanding trial sites internationally, with discussions ongoing for potential sites in Canada and Europe [69] Q&A Session Summary Question: Has the final data from OVATION 2 been presented to the FDA? - Management has not yet presented the OS data to the FDA but is excited about the continued improvement and plans to replicate findings in the Phase III trial [24] Question: What are the potential interim analysis cut points for the OVATION 3 trial? - The first interim analysis is expected about a year after full enrollment, designed to allow for quicker action if a significant effect is observed [35] Question: Will there be updates from the MRD study in 2026? - Updates will depend on interactions with the study PI, with ongoing discussions about presenting insights to the medical community [46] Question: How is the Phase III trial being financed? - The trial is structured traditionally with contracts for start-up fees and fees as patients are treated, leveraging standard care payments where possible [71]

Financial Data and Key Metrics Changes - As of December 31, 2025, cash and cash equivalents were $8.8 million, reflecting disciplined cash management and net proceeds from warrant exercises and targeted ATM usage during the year [18] - Research and development expenses for 2025 were $7.8 million, significantly lower than 2024, primarily due to the completion of the OVATION 2 study [18] - General and administrative expenses decreased by 8% year-over-year through streamlined operations [19] - Net loss for 2025 was $14.5 million or $6.83 per share, compared to $18.6 million or $16.94 per share in 2024, indicating meaningful improvement driven by cost discipline [19] Business Line Data and Key Metrics Changes - The proprietary IL-12 immunotherapy, IMNN-001, is advancing in the OVATION 3 pivotal phase III study, with strong momentum following the transformational year in 2025 [4][5] - IMNN-001 demonstrated a median overall survival benefit of 14.7 months in the OVATION 2 study, with patients treated with PARP inhibitors showing a median increase in overall survival of more than 2 years [7][12] Market Data and Key Metrics Changes - Enrollment in the OVATION 3 trial is ahead of plan, with 7 clinical sites actively enrolling patients and up to 43 additional centers under evaluation [10] - The trial aims to have approximately 80 patients enrolled within the next 12 months, with enrollment completion expected in 2029 [11] Company Strategy and Development Direction - The company is focused on advancing the OVATION 3 study while navigating a challenging capital markets environment, employing a multi-pronged financing strategy [15][16] - The strategic reorganization aims to reduce non-essential costs and sharpen operational focus exclusively on OVATION 3 [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing momentum of the OVATION 3 trial and the potential for significant value creation for shareholders [4][15] - The company is encouraged by continued interest in potential non-dilutive partnerships for its TheraPlas technology platform and IMNN-001 [16] Other Important Information - The final analysis of the OVATION 2 study showed unprecedented overall survival benefits, which have generated significant interest from clinical investigators [13][14] - The company is actively engaging with the medical community to translate the value of IMNN-001 for newly diagnosed women with advanced ovarian cancer [30] Q&A Session Summary Question: Has the final data from OVATION 2 been presented to the FDA? - Management has not yet presented the OS data to the FDA but is excited about the continued improvement and plans to replicate findings in the phase III trial [24] Question: What are the potential cut points for interim analyses in the OVATION 3 trial? - The first interim analysis is expected about a year after full enrollment, designed to allow for quicker action if a significant effect is observed [35] Question: How has the final data from OVATION 2 changed the partnership environment? - There has been renewed interest and inquiries for partnerships following the release of the final data [37] Question: Will there be updates from the MRD study in 2026? - Updates will depend on interactions with the study PI, and there are plans to present insights from the MRD study in the medical community [46] Question: How is the phase III trial being financed? - The trial is structured traditionally with contracts for start-up fees and fees as patients are treated, leveraging standard of care payments where possible [71]

Summary of Bitfarms Conference Call (March 31, 2026) Company Overview - **Company Name**: Bitfarms, transitioning to **Keel Infrastructure** - **Industry**: Data Center Infrastructure, focusing on High-Performance Computing (HPC) and Artificial Intelligence (AI) - **Re-domiciliation**: Effective March 31, 2026, Bitfarms will no longer be a Canadian company and will operate as a U.S. company [3][4] Strategic Focus - **Shift in Business Model**: Transitioning from Bitcoin mining to 100% focus on HPC and AI infrastructure [3] - **Infrastructure Development**: Positioning as a pure infrastructure developer and owner, not competing in HPC and AI compute or cloud space [4] Site Locations and Capacity - **Total Capacity**: Approximately **2.2 GW** of energized, secured, and expansion capacity across Pennsylvania, Quebec, and Washington [5] - **Pennsylvania Sites**: - **Sharon**: 110 MW - **Panther Creek**: 350 MW secured, potential expansion to 500 MW [5][6] - **Scrubgrass**: Potential capacity of 1.3 GW, with a 750 MW load study in progress [6][7] - **Quebec Sites**: 170 MW total, focusing on consolidating three Bitcoin mining sites into a new campus [8] - **Washington Site**: 18 MW under development [7] Competitive Advantages - **Location**: Sites are strategically located in northern states, providing cooler climates for higher efficiency and lower operational costs [9][10] - **Market Position**: Concentration in high-demand markets (Pennsylvania, Quebec, Washington) with significant barriers to entry [10] Market Dynamics and Tenant Engagement - **Latency Considerations**: Proximity to major metropolitan areas enhances appeal for inference applications, which are expected to drive demand [11][12] - **Tenant Selection**: Focus on investment-grade rated customers or those with credit wraps to ensure lower financing costs [29][30] Milestones and Catalysts - **Key Catalysts for 2026**: 1. Continued execution on site advancements, permitting, and construction [16][17] 2. Conversion of expansion capacity into secured capacity [18] 3. Delivery of commissioned sites in 2027, reducing development risk [19][23] - **Timeline Expectations**: Panther Creek expected to come online in 2027, with other sites following [23][47] Financial Position and Revenue Streams - **Bitcoin Holdings**: Currently holding under **2,500 Bitcoin**, with plans to wind down Bitcoin mining exposure [78][80] - **Liquidity Management**: Strong liquidity position to support operations without relying on Bitcoin mining revenues [80][81] Regulatory and Market Challenges - **Data Sovereignty in Canada**: Canadian regulations require data to be stored within the country, creating higher barriers to entry and potentially higher lease values [82][83] - **Expansion Opportunities**: Engaging with local utilities for additional power generation to support data center growth [40][42] Future Outlook - **Long-term Strategy**: Focus on energy markets with excess capacity and stable pricing, avoiding volatile markets like Texas [85][86] - **Market Adaptation**: Willingness to explore new opportunities as market conditions evolve [87] This summary encapsulates the key points discussed during the Bitfarms conference call, highlighting the company's strategic shift, operational capacity, competitive advantages, and future outlook in the HPC and AI infrastructure market.

Financial Data and Key Metrics Changes - Total revenues for 2025 decreased by 12% to $6.1 million compared to $6.9 million in 2024 [17] - Hardware revenues increased over 100% to $1.3 million in 2025, driven by increased purchases of biometric solutions [17] - Service revenue grew by 6% to $1.2 million due to a growing customer base and new deployments [17] - Gross margin for 2025 was 77.5%, down from 81.4% in 2024, primarily due to the revenue mix [18] - Net loss increased to $4.6 million or $0.69 per share in 2025, compared to a loss of $4.3 million or $2.09 per share in 2024 [19] Business Line Data and Key Metrics Changes - License fee revenue decreased by 26% in Q4 2025, while hardware revenue increased by 85% [17] - Service revenues decreased by 10% in Q4 2025, reflecting deployment timing and other factors [17] - Gross margins on license fees improved to 91% in 2025 from 88% in 2024 due to selling branded products [18] Market Data and Key Metrics Changes - The global authentication solutions market is estimated to be $23 billion in 2025 and projected to reach almost $100 billion by 2035, representing a compound annual growth of almost 16% [8] - There is a significant shift towards passwordless authentication, with over 70% of enterprises moving in that direction [9] Company Strategy and Development Direction - The company is focusing on selling only BIO-key branded solutions in the EMEA region, which is expected to enhance gross margins and growth prospects [6] - A strategic transition in the EMEA division is anticipated to yield benefits in 2026 and beyond [26] - The company launched a Defense and Intelligence Cybersecurity Initiative in 2025 and is seeing momentum in defense and financial sectors [11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for Q1 2026, anticipating revenue of approximately $2.2 million, a 37% increase over Q1 2025 [4] - There is a growing urgency from customers in securing access to mission-critical systems, particularly in military, defense, and financial services [5] - The company aims to reach breakeven and profitability in 2026, supported by a solid cash position and expected cash receipts [15] Other Important Information - The company ended 2025 with $2.7 million in cash, up from $438,000 at the end of 2024, and increased book value to $7.6 million [15][20] - The company is investing in R&D, with a new FBI FAP 20 certified EcoID III fingerprint scanner introduced in Q4 [12] Q&A Session Summary Question: Clarification on 2025 revenue performance - Management explained that the revenue decline was impacted by a significant contract renewal with a foreign bank in 2024, which was not repeatable in 2025 [24][25] Question: Insights on first quarter revenue target - Management confirmed that the majority of the anticipated $2.2 million revenue for Q1 2026 will likely come from license revenue, with strong hardware revenue as well [33][34] Question: Opportunities in various sectors - Management highlighted significant opportunities in defense, government, and financial services, with a focus on regulated industries [36][38] Question: Updates on R&D expenses - Management indicated that R&D expenses are expected to remain stable, with significant investments already made for upcoming product enhancements [45] Question: Potential for achieving break-even results - Management stated that the goal is to achieve break-even or profitability in early 2026, with ongoing efforts to reduce cash burn [52][55] Question: Evidence of U.S. businesses adopting passwordless solutions - Management confirmed that there is strong new business growth, particularly through partnerships that enhance market reach [56][57]

Summary of Shoals Technologies Group Update - March 31, 2026 Company Overview - **Company**: Shoals Technologies Group (NasdaqGM:SHLS) - **Industry**: Battery Energy Storage Solutions (BESS) Key Points and Arguments Importance of Battery Energy Storage - Battery energy storage has gained significant importance due to the increasing demand for reliable energy solutions, particularly in data centers and renewable energy projects [1][2] - The evolution of battery technology has led to larger, more efficient systems capable of providing multiple hours of energy duration, driven by advancements in lithium-ion technology and alternative storage solutions [6][7] Market Dynamics - The market for battery energy storage systems is evolving, with a notable shift towards DC coupled installations, which offer advantages in cost and efficiency compared to AC coupled systems [11][16] - Approximately 80% of current storage projects are AC coupled, while 20% are DC coupled, primarily due to operational flexibility and revenue generation capabilities of AC systems [14][19] Product Value Proposition - Shoals' products are designed to simplify the integration of battery storage with solar energy systems, allowing for reduced inverter requirements and lower capital expenses [12][16] - The company emphasizes its ability to customize solutions for specific customer needs, differentiating itself from larger multinationals that offer standard products [61][95] Data Center Market Insights - The demand for battery energy storage in data centers is driven by the need for backup power, power quality, and speed to interconnection, particularly as data centers increasingly rely on AI and high-performance computing [31][42] - The sales cycle for battery energy storage solutions in data centers typically ranges from 9 to 18 months, with a growing interest in using BESS as a firming resource for grid stability [43][44] Competitive Landscape - Shoals competes with major players like Eaton, Schneider, and Siemens, but its focus on customization and high mix, high volume production allows it to stand out in the market [95][96] - The company is positioned as a bankable partner for large-scale projects, contrasting with smaller panel shops that may lack the financial stability to support extensive orders [61][95] Future Opportunities - The potential market for battery energy storage in data centers is substantial, with estimates suggesting a 10-15 gigawatt annual market in the U.S. However, the exact addressable market for Shoals remains uncertain due to the nascent nature of BESS applications [77][78] - Shoals is exploring new product developments, including skidded power electronics, to further enhance its offerings and meet the evolving needs of the energy storage market [58][86] Conclusion - Shoals Technologies Group is well-positioned to capitalize on the growing demand for battery energy storage solutions, particularly in the data center sector, by leveraging its expertise in DC coupled systems and its commitment to customization and scalability [1][61]

Financial Data and Key Metrics Changes - For Q4 2025, the company reported fee revenues of $22.9 million, a 67% increase from $13.8 million in Q4 2024 [7] - The net income for Q4 2025 was $0.6 million or $0.02 per share, compared to a net loss of $0.8 million or $0.03 per share in Q4 2024 [7] - Adjusted EBITDA for Q4 2025 was $3.3 million, up from $0.9 million in the previous year [7] - For the full year 2025, fee revenues were $61.9 million, a 16% increase from $53.5 million in 2024 [8] - The net loss for 2025 was $1.9 million or $0.06 per share, improved from a net loss of $4.7 million or $0.13 per share in 2024 [8] - Adjusted EBITDA for 2025 was $4.7 million, a 139% increase from $2 million in 2024 [8] - Operating cash flow generated in 2025 was $14 million, increasing cash balance to $4.9 million from $1.4 million at the end of 2024 [8] Business Line Data and Key Metrics Changes - The company purchased $24.2 million in new equipment, primarily single node channels, enhancing operational capacity [4] - Over 180,000 channels of legacy and new equipment are now available for service [5] - General and administrative expenses were reduced by 9% in 2025 compared to 2024 [5] Market Data and Key Metrics Changes - Activity levels increased in Q4 2025 with four crews operating in the lower 48 states and two in Canada [10] - The company resumed Canadian operations in Q4 2025 and anticipates a successful first quarter in 2026 [10] Company Strategy and Development Direction - The company is focusing on expanding its customer base to include unconventional exploration such as carbon capture and geothermal projects [11] - There is a significant competitive advantage due to high channel count and quality of vibrator energy source units [5] Management's Comments on Operating Environment and Future Outlook - Management noted an uptick in bid opportunities and utilization over the last three quarters, although the impact of geopolitical conflicts on demand remains uncertain [16] - The company expects continued improvement in profitability metrics into 2026 [6] Other Important Information - A revolving credit facility was established with a maximum lender commitment of $5 million, with no balance outstanding as of December 31, 2025 [9] - A capital budget of $3 million for 2026 was approved, including final payments for equipment purchases [9] Q&A Session Summary Question: How would you characterize the quality of the service technology today versus five to ten years ago? - The company highlighted the transition to single node technology, reducing equipment weight from 10 lbs to 1 lb, which enhances operational efficiency and reduces field footprint [16] Question: Have you seen any changes in demand for services due to the conflict in the Middle East? - Management observed an increase in bid opportunities but noted that the demand may not be significantly influenced by the conflict, as budgets were set prior to the events [17]